|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent Immunovant insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why Immunovant insider buys are important for investors to follow.
Date | Insider | Price | Amount |
10-2-2023 Insider Buy |
Sciences LTD. Roivant
|
$38.00
CAGR »
|
$58,000,008.00 1,526,316 shares |
9-30-2022 Insider Buy |
Atul Pande Director |
$5.60
CAGR »
|
$84,000.00 15,000 shares |
10-6-2022 Insider Buy |
Sciences LTD. Roivant
|
$6.00
CAGR »
|
$2,500,002.00 416,667 shares |
9-29-2022 Insider Buy |
Frank Torti Director |
$5.81
CAGR »
|
$116,200.00 20,000 shares |
8-27-2021 Insider Buy |
Douglas J. Hughes Director |
$8.24
CAGR »
|
$150,355.28 18,247 shares |
8-20-2021 Insider Buy |
George V. Migausky Director |
$7.65
CAGR »
|
$53,550.00 7,000 shares |
8-13-2021 Insider Buy |
Atul Pande Director |
$7.98
CAGR »
|
$39,900.00 5,000 shares |
8-10-2021 Insider Buy |
Andrew J. Fromkin Director |
$7.90
CAGR »
|
$43,450.00 5,500 shares |
9-11-2020 Insider Buy |
Julia G. Butchko Chief Dev. & Tech. Officer |
$38.17
CAGR »
|
$190,850.00 5,000 shares |
9-4-2020 Insider Buy |
Sciences LTD. Roivant >10% Owner |
$33.00
CAGR »
|
$12,540,000.00 380,000 shares |
4-16-2020 Insider Buy |
Sciences LTD. Roivant >10% Owner |
$14.50
CAGR »
|
$15,000,003.50 1,034,483 shares |
Also See: Institutional Holders of IMVT
Also See: SEC filings
Below we present the annualized performance delivered by Immunovant stock since 10-2-2023 (the date of the most recent
insider purchase). The performance of the investment from the time Immunovant insider buying occurred is the ultimate
test of whether insiders were right about IMVT being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/03/2023 |
|
End date: |
05/01/2024 |
|
Start price/share: |
$34.28 |
|
End price/share: |
$28.52 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-16.80% |
|
Annualized Gain: |
-29.07% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$8,320.00 |
|
Years: |
0.58 |
|
Immunovant Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Immunovant insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding IMVT
|
|